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INVESTIGATING ROLES OF 2 NOVEL EKLF TARGETS INVOLVED IN

ERYTHROPOIESIS

ROSE GOTT
ABSTRACT

Erythrocytes are primarily comprised of the oxygen carrying protein hemoglobin.
Genetic mutations causing defects in the proper synthesis of hemoglobin result in various

anemias. It is during the last phases of terminal erythroid differentiation that hemoglobin
levels rise, making it a focus for therapeutic research.

Fetal hemoglobin is comprised of α-globin and gamma globin, then after a change

in gene expression called hemoglobin switching which takes place after birth, adult
hemoglobin is comprised of α-globin and beta globin. We investigated hemoglobin
switching and erythroid terminal differentiation by focusing on the master erythroid

transcription factor Erythroid Kruppel-like Factor (EKLF). Data led to identifying two
novel EKLF targets. The first, Pumilio 1 (PUM1), is a protein that is known as a post

transcriptional repressor and not been studied in erythrocytes until now. Our work

indicates that PUM1 does indeed work as a post transcriptional repressor of y-globin in

adult cells. Data also shows that if PUM1 levels are lowered that y-globin levels rise
significantly without altering β-globin levels or stalling progression through erythroid

terminal differentiation. Together, this data shows that PUM1 mediated posttranscriptional regulations has a significant role in hemoglobin switching and could serve
as an excellent therapeutic target since the induction of y-globin has been shown to
ameliorate symptoms of hemoglobinopathies.
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The second EKLF target investigated is Inner Centromere Protein (INCENP).
This protein has a major role in lining up chromosomes and microtubules for successful
cytokinesis. This preliminary investigation showed that there is an increase in ploidy
when INCENP levels are lower in erythroid cells.
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CHAPTER I

INTRODUCTION

1.1 Erythrocyte Differentiation
Erythrocytes constitute more than 80% of the cells in the human body (1). These

7-8 micrometer cells are comprised primarily of hemoglobin, which enables them to
carry oxygen from the lungs to all other tissues and organs of the body for their

approximately 120-day lifespan (2). To accomplish this feat, ~2 million erythrocytes
finish terminal differentiation per second. Production of erythrocytes begins when a stem
cell commits to being an erythroid lineage specific progenitor, then commits once more
to being a proerythroblast. The terminal differentiation process from a proerythroblast to

an erythrocyte is a quick progression through several stages. As the proerythroblast
advances through them the overall size of the cell will decrease and the cell will

accumulate hemoglobin, these are the basophilic and polychromatic stages. Finally, the
nucleus will condense and polarize in the orthochromatic stage, eventually being
extruded (3). The final enucleated cell that is released into the blood stream is a round

reticulocyte which will continue to mature into the characteristic biconcave shape

associated with erythrocytes within 48 hours. This shape change is a result of shifts in
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the volume to surface area ratio of the cell and enables it to remain pliable and able to

easily contort in small circulation spaces such as capillaries.

Figure 1 Erythroid terminal differentiation.

The stages of erythroid terminal differentiation to the point of enucleation.
Reticulocytes are released into the blood stream where they continue to mature into an
erythrocyte. Red line just prior to enucleation shows where the process stops in a cell
that lacks EKLF and has not been able to exit cell cycle.
Source: Gnanapragasam, M. N., McGrath, K. E., Catherman, S., Xue, L., Palis, J., &
Bieker, J. J. (2016). EKLF∕KLF1-regulated cell cycle exit is essential for erythroblast
enucleation. Blood, 128(12), 1631-1641. https://doi.org/10.1182/blood-2016-03-706671
1.2 Erythroid Kruppel-like Factor

Fully understanding the mechanisms involved in erythropoiesis is a crucial part of
understanding blood-based disease processes and developing treatments for them. In

1993 Dr. James Bieker discovered Erythroid Kruppel-like Factor (EKLF),a master
transcription factor regulating many genes during erythropoiesis (4). This was the first

Kruppel-like Factor (KLF) that was identified and is often identified as EKLF/KLF1. For
the purposes of this paper, it will simply be referred to as EKLF. The structure of EKLF

includes three C2H2 zinc fingers for DNA binding at the C terminus and a proline rich
transactivation domain near the N terminus (5). It binds to DNA on a cognate target

element of 5' CCMCRCCN3' (6). Years of research have shown that EKLF is intricately
involved in lineage commitment (7), expression of globin proteins, and terminal erythroid
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differentiation, and other roles. However, the mechanisms for many of these roles are
still being investigated (8). The research in this paper focuses on systems participating in

globin expression and terminal differentiation.

It has previously been established using molecular and genetic research that
EKLF is a crucial factor in globin expression (9,10). The motif that EKLF binds to is
5'CCMCRCCN3, and it is found in the promotor element of α-like and β-like globin

genes. This demonstrates that EKLF is responsible for globin expression in the cell, and
therefore plays a significant role in hemoglobin switching (11).
One of the reasons such large numbers of erythrocytes can be produced quickly is

because the cells are still proliferating in early stages of terminal differentiation. This
proliferation is largely driven by EKLF upregulating E2F2 which promotes the cells
transition to S phase and cell division. In later stages, when the nucleus has condensed

and polarized, EKLF upregulates the cell cycle inhibitors p18 and p27, which promotes

cell cycle exit and enucleation (12). The role of EKLF in erythropoiesis is so essential
that EKLF -/- mice die at E15 due to extreme anemia (13).
To further investigate the role of EKLF in erythropoiesis, Dr. MN

Gnanapragasam performed RNA-seq analysis on EKLF+/+ and -/- erythroid cells before
and after terminal differentiation and merged this with chromatin immunoprecipitation

(ChIP) followed by next generation sequencing analysis (ChIP-seq). This data was used

in our lab to initiate the research projects discussed in this paper.
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Figure 2 RNA-seq and ChIP-seq of EKLF show that shows EKLF binds to the
PUM1 gene to activate transcription
RNA-seq shows the proportion of PUM1 transcripts in both EKLF +/+ and EKLF
-/- erythroid cells before and after terminal differentiation. ChIP-seq shows EKLF binds
to the PUM1 gene to activate transcription. This means it is a direct target of EKLF.
Together, this data shows that EKLF upregulates PUM1 transcription during terminal
differentiation. * P<0.05; ***P<0.0005
Source: Dr. MN Gnanagragasam.

1.3 Hemoglobin
Hemoglobin is a heterotetrametric protein, of which each subunit is capable of
carrying one oxygen molecule. Each of the approximately 200 million hemoglobin

molecules in a single erythrocyte can carry a maximum of four oxygen molecules. This

transport of oxygen throughout the body is the primary purpose of erythrocytes.
4

In the earliest stages of ontogenesis, primitive erythrocytes expressing epsilon

globin (HBE) are produced in the yolk sac. Later in gestation, fetal erythrocytes are
produced in the liver. They produce fetal hemoglobin (HbF), which consists of two aand two y-subunits per protein (14). Fetal hemoglobin has a high affinity for oxygen,

making it ideal for binding to oxygen in the lower oxygen environment of the uterus.
There are two genes for y-globin (HBG1 and HBG2), the result of an ancestral

duplication event. The globin proteins themselves vary only by one amino acid at residue
136, an alanine for HBG1 and glycine for HBG2. Their transcripts however contain

different coding in their 3’ untranslated region (UTR).

After birth, the location of erythrocyte production transitions to the bone marrow.
During this time, the composition of almost all hemoglobin proteins shifts from □ -and γ-

globin to □-and β-globin. Approximately 98% of adult hemoglobin (HbA) contains two
a-and two β-subunits (15). The other 2% of adult hemoglobin (HbA2) contain two a-

globins and two δ-globin. δ-globin does not have a very strong promotor region and is
produced in relatively small amounts. β-globin has a marginally lower oxygen affinity
when compared to y-globin which makes it well suited the higher oxygen levels of the
lungs. This change from γ to β-subunits is known as hemoglobin switching. Figure 3

The epsilon, y-and β-globin genes are found in a single gene cluster on

chromosome 11. □-globin genes, which comprise 50% of all the hemoglobin proteins,
are located on chromosome 16 (16). Distal regulatory elements, known as locus control

regions (LCR) loop around to interact with individual globin genes (17). At any given
time only one LCR to globin gene interaction is possible on each chromosome (18).

5

Figure 3 Hemoglobin switching is based on developmental stage

This graph shows the percentage of total hemoglobin subunit synthesis at
developmental stages from conception to 15 months post birth. By three months after
conception 50% of globin synthesis is and will remain □-globin. This is due to both fetal
and adult hemoglobin containing two alpha units each. The phenomenon of the other
almost 50% of globin synthesis being fetal y-globin prebirth changing over to adult βglobin post birth that is called hemoglobin switching.
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Developmental
stage

Adult

Fetal

Figure 4 Hemoglobin synthesis locations, globin subunits involved and globin gene
locations
The genes for ε, y, δ, and β-globin are all found on chromosome 11. The locus
control region (LCR) loops to interact with one gene at a time. This figure shows βglobin gene cluster, the LCR, the location of erythropoiesis both pre and post birth, and
the composition of the dominant hemoglobin protein. The possible blocking or reversing
of this hemoglobin switching has been the basis of research for many years in the hopes
of ameliorating β-hemoglobinopathies.
Source: Vinjamur, D. S., Bauer, D. E., & Orkin, S. H. (2018). Recent progress in
understanding and manipulating haemoglobin switching for the
haemoglobinopathies. British journal of haematology, 180(5), 630-643.
https://doi.ors/10.1111/bjh. 15038
1.4 β-Hemoglobinopathies
Abnormal production of the β-globin protein inhibits the ability of hemoglobin to

efficiently carry oxygen. The resultant diseases are labeled β-hemoglobinopathies and
are the most common genetic disorders in the world (19). They are predominately found

in the populations of underdeveloped countries, although that epidemiology is changing
with the increasing prevalence of global travel (20). While there are multiple β-
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hemoglobinopathies, by far the most common are sickle cell disease (SCD) and βthalassemia.

SCD is a qualitative disease caused by a single point mutation in the seventh

codon of the β-globin gene. This change of an adenine to a tyrosine changes the amino
acid coding from a hydrophobic glutamic acid to a hydrophilic valine (21). The

hemoglobin formed with this alternative amino acid is called sickle hemoglobin (HbS).

The resultant protein shape, which is normally globular, instead forms fibrous strands that
contort the biconcave shape of the erythrocyte into a sickle shape. The resultant cells are
sticky, and their cell membranes are not as pliable for moving through capillaries (22).

This makes the cells prone to clumping in smaller areas of circulation and causing blood
clots.

β-thalassemia is quantitative, and the severity of disease is linked to the

proportion of hemoglobin that is not fully functional. Many different mutations have
been identified in patients, generally in the β-globin promoter (23). A patient with

heterozygous mutations will have less severe symptoms because there is enough normal
hemoglobin to help the body function properly. Homozygous mutations cause severe
symptoms including slow growth, facial bone deformities, extreme fatigue, and

abdominal swelling (24). Current therapies rely heavily on frequent blood transfusions
with the most effective option being a bone marrow transplant. Unfortunately, matching

bone marrow donors are difficult to find, and the procedure comes with many of its own

risks. For those receiving transfusions, even with concurrent chelation therapy, there is
often a deleterious buildup of iron in the body, shortening the expected lifespan.
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Many clinical studies have shown that the reinduction of y-globin to produce HbF
can ameliorate the symptoms of these diseases (25).

Erythrocytes that have shown an

appreciable amount of HbF are labeled as F-cells. The erythrocytes themselves are still
adult and are not phenotypically identical to fetal erythrocytes, but a high proportion of
their hemoglobin contains HbF (26). Patients with β-hemoglobinopathies who also have
an appreciable number of F-cells have noticeably milder clinical symptoms (27). In βthalassemia the F-cells can carry much needed oxygen, and in SCD the HbF prevents

some of the polymerization into fibers caused by HbS, thus reducing sickling (28).

In times of hemoglobin stress such as massive blood loss, F-cells can be found in
the bloodstream for a short time at a level above the normal range of less than 1%.
However, some patients have been shown to possess mutations in the regulatory regions

of β-globin, which partially prevented hemoglobin switching after birth. These patients,
some of whom also have SCD, show varying but significant amounts of F-cells in their

blood, and therefore exhibit no clinical symptom. This condition of incomplete

hemoglobin switching is known as hereditary persistence of fetal hemoglobin (HPFH)

(29). Altogether, this makes the reinduction of HbF a desirable treatment for βhemoglobinopathies. Given that previous research has shown a direct relationship

between EKLF and globin expression, as well as several blood disorders (30-32), EKLF

is a promising avenue of study for HbF reintroduction.
Hydroxyurea is currently the most common medicine given to raise levels of HbF.

This is accomplished by suppressing erythropoiesis and depends on functioning erythroid

producing bone marrow (33). Developing other treatments and methods to increase HbF
in patients has been the focus of research for many years. The research in this paper
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examines novel targets of EKLF to not only elucidate the mechanism of hemoglobin
switching and erythroid terminal differentiation, but to pave the way for possibly

discovering more effective therapies.
1.5 Pumilio 1

We analyzed the ChIP-seq and RNA-seq data for EKLF and found a novel target
called Pumilio1 (PUM1). PUM1 is a member of the Puf family of proteins, and generally
acts as a post transcriptional repressor. An important part of post transcriptional gene

regulation (PTGR), PUM1 has been found to have cell type specific roles. These roles
are often enhanced by various protein cofactors (34). While PUM1 has been well studied

in relation to PTGR and many disease processes such as cancer, neurodegeneration,
infertility (35), body and organ size (36), and more, it has not been studied in
erythropoiesis until now.
PUM1 was discovered in Drosophila during embryonic development research. It

binds to mRNA on the PUM1 recognition/response element (PRE) located on the 3’
untranslated region (UTR). The highly conserved consensus binding site for the PRE is
5’UGUAHAUA3’ (37). We searched the human genome library and found that HBG1 is

the only globin protein that contains a PRE in its 3’ UTR (Figure 4).
Much previous research has shown that PUM1 primarily regulates mRNA two

ways; by shortening mRNA half-life and by inhibiting translation. Previous studies have
shown that mRNA half-life is shortened when PUM1 recruits the Ccr4-Not complex

(CNOT), which marks the mRNA for degradation (38). To inhibit translation efficiency,
it interferes with the poly-A binding protein (PABP) which effectively blocks translation
initiation.
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One disease process that is directly linked to PUM1 dysfunction is called Pumilio

1-associated developmental disability, ataxia, and seizure (PADDAS). Caused by a
PUM1 mutation, specific to the patient, the symptoms include the developmental delay,

ataxia and seizure listed in the name (39). In this research we report on an individual
diagnosed with PADDAS who was born with a novel heterozygous mutation in the
PUM1 binding domain (p. (His1090Profs*16); c. 3267_3270delTCAC). This deletion

causes a frameshift which results in a proline replacing a histidine, followed by 16 new
amino acids and a premature stop codon. We also obtained a blood sample from a
healthy parent to compare for our analysis. Institutional review board (IRB) was granted

by Cleveland State University.

Figure 5 A search of the human genome showed a binding site for PUM1 in the 3’
UTR of HBG1
PUM1 is known in other cell types to bind to a conserved binding sequence in the
3’ UTR of mRNA. It is then able to exert post transcriptional repression on those
transcripts by shortening half-life and inhibiting translation. HBG1 is the only globin
gene to contain this sequence, marking it as a probable target for PUM1 repression.
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1.6 Inner Centromere Protein

Another novel target for EKLF is Inner Centromere Protein (INCENP), also

upregulated in terminal differentiation (Figure 5). A member of the chromosomal

passenger complex (CPC), it has an important role in cytokinesis (40). Considered a

master regulator of mitosis, the CPC consists of INCENP, Survivin, Borlean, and Aurora
B kinase (41). The CPC is instrumental in many aspects of late mitosis, from

centromeric cohesion to correctly lining up chromosomes and attaching them to
microtubules (MT) for proper separation in anaphase. It has also been shown to delay
abscission in the event of chromatin bridging. The CPC tightly associates with

chromosomes in early mitosis and quickly disassociates during the transition to anaphase,
moving to associate with the microtubules and midbody structure (42). While INCENP
itself is only a single helictical protein, it is considered the structural protein of the CPC
with very dynamic mitosis stage specific localization. The N-terminus contains a domain

for associating with centromeres, while the C-terminus contains that MT association
domain (43).

Mutations and dysfunction of the CPC is associated with the development of

cancers (44,45), due to the uneven distribution of chromosomes if the CPC fails to halt

cytokinetic abscission when there is bridging (46). Mutations that lead to complete non
function of INCENP are embryonically lethal (47).
Given the prolonged proliferation in the early points of differentiation and quick
succession through the stages of terminal differentiation, erythrocytes cycle through

many cytokinetic events. As a novel target of EKLF, INCENP may be upregulated to

maintain successful cytokinesis and normal nuclear content/morphology.
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The CPC and INCENP have been studied in many cell types due to its importance
in many developmental processes and its role in cancer development, but it has not been
studied in erythrocytes until now.

Figure 6 RNA-Seq and ChIP-Seq show INCENP to be novel target of EKLF
ChIP-seq shows EKLF binds to INCENP gene as compared to Necdin which is
not a target. RNA-seq shows the proportion of INCENP transcripts in both EKLF +/+
and EKLF -/- erythroid cells after terminal differentiation, showing how the presence of
EKLF increases the expression of INCENP. Together, this data shows that EKLF
upregulates INCENP transcription during terminal differentiation. ***P<0.05
1.7 Auxin Induced Degron System
Molecular biology uses knockdown and overexpression studies to investigate

protein function in vivo. The levels of the protein of interest (POI) are knocked down
and then overexpressed while studying the cellular phenotype under each condition. The

most common way to achieve this is using a plasmid. For knockdown, a plasmid uses

host polymerases to produce an interfering RNA (RNAi). This RNAi then binds to the
cells’ RISC complex and is processed to use as a guide RNA to determine which mRNA
to bind to and cut, the damage marking them for degradation. Since there are fewer

transcripts, less of the POI is translated. Conversely, plasmids can be used to simply
introduce more of the POI transcripts so that higher than normal endogenous levels can
13

be achieved. The designing, reproduction, and introduction of these plasmids into cells is
time consuming and the reduction or overproduction of protein will occur with no

external means of signaling or control.
To attain faster results and maintain more control over protein levels, scientists

have designed degron systems that respond to temperature, light, small molecules, or

expression of other proteins. A degron system is a domain on the plasmid that induces
degradation of the POI. An auxin induced degron (AID) system uses the plant hormone
auxin to signal the cells’ own ubiquination system to mark the POI for degradation by the

26S proteosome as it is being translated (48). This direct control at the protein level is

faster, extremely specific, and reversible.
The plasmid itself includes an F-box related protein called TIR1. When auxin is
introduced to the cellular media it will bind to TIRI which will signal the F-box to recruit
the host cells E2 protein. E2 is part of the ubiquitin ligase complex and will be used to
mark the POI with a ubiquitin chain. This will signal the POI for degradation by the 26S

proteosome as it is being translated (49). Auxin is a plant protein that is not found in
animal cells so there are no background levels in the cell or in any growth media. The

level of degradation is directly proportional to the amount of auxin added to the media

and will stop altogether if auxin is removed. The half-life of degradation is

approximately 30 minutes, making this a fast, tightly controllable, and easily reversible
means of protein level control. This also means that the cell has no time to adapt to the

changes in protein levels and use any compensatory pathways.
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Figure 7 Auxin induced degron system (AID) functional parts without and with
auxin present
The functional parts of an AID include AID itself, the F-box, consisting of Skp1
and Cul1, and the F-box associated protein TIR1. When auxin is present it will bind to
TIR1, activating the F-box. Cul1 is heterodimerized to Rbx1 which, when activated by
the F-box, interacts with E2. A part of the host cells’ ubiquitin ligase complex, E2
recruits the binding of a ubiquitin chain on the protein of interest. The 26S proteosome
(not pictured) will then degrade protein.
1.8 Hypothesis and Projects

Hypothesis 1
In adults, EKLF upregulates PUM1 in terminal erythroid differentiation. During
the final stages when hemoglobin is accumulating, PUM1 post-transcriptionally represses
the expression of y-globin. Therefore, if PUM1 levels are lowered, y-globin levels will

increase, making PUM1 activity a mechanism in hemoglobin switching.

Project 1
Using erythroid progenitor cells, the role of PUM1 in terminal differentiation will

be investigated. First, by loss of function analysis to determine if y-globin levels are
affected. Second, by determining mechanisms used by PUM1 to affect said levels using
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various testing methods. Based on previous PUM1 research in other cell types, focus will

be on post-transcriptional regulation.

It is important to note that this was a large project in which every member of our
lab contributed. The results, data and discussions in this paper will focus on aspects that
the writer is directly responsible for and will not include experiments that they did not

have a role in performing.

Hypothesis 2
Our unpublished data shows that EKLF upregulates INCENP in terminal
erythroid differentiation. During the quick succession through these phases many

cytokinetic events occur, making INCENP an important factor in maintaining nuclear

integrity. Therefore, if INCENP levels are decreased, incidence of abnormal nuclear
morphology in terminal differentiation will increase.
Project 2

This preliminary investigation into the role of INCENP in successful cytokinesis

in terminal erythroid differentiation will also include knockdown studies. A loss of
function study will be performed, and nuclear morphology evaluated. Also, INCENP

protein level responsiveness to varying levels of auxin using a plasmid containing an AID
will be explored.
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CHAPTER II

MATERIALS AND METHODS

2.1 Cell lines and Cell Culture
The cell line used to study hemoglobin switching were human umbilical cord
derived erythroblast progenitor (HUDEP2) previously immortalized by the introduction

of HPV16-E6/E6 transgene. These genes inhibit retinoblastoma tumor suppressor protein

(pRB) and p53 from functioning as cell cycle regulators which effectively blocks
senescence.

Expanding cells were cultured in 6-well plates and maintained in an expansion
media consisting of serum free media (SFEM) supplemented with 50ng/mL human stem

cell factor (hSCF), 3IU/mL human Erythropoeitin (hEPO), 2% penicillin/streptomycin,

1μg∕mL doxycycline and 0.4μg∕mL dexamethasone.
To induce differentiation, cells were washed with phosphate buffered saline

(PBS) then put into the first of three erythroid differentiation medias (EDM). The base

EDM consisted of Iscove’s modified Dulbecco’s Media (IMDM), 5% fetal bovine serum
(FBS), 2% penicillin/streptomycin, 1% L-glutamine, 330μg∕mL human holo-transferrin,

10μg∕mL insulin, 3IU∕mL hEPO.
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The ten-day differentiation process began with cells being cultured for four days
in growth phase media (EDM-2) which is EDM with 100ng/mL hSCF, and 1μg∕mL

doxycycline added.
Cells were then washed again and put into maturation phase media (EDM-3)
which consisted of EDM with 1ug/mL of doxycycline for three days. After washing

again cells were cultured in EDM media with no additives.
To study cellular morphology in differentiation, murine extensively self-renewing

erythroblasts (mESREs), were utilized. EKLF+/+ and -/- primary cells were previously
harvested from E12.5 fetal mouse livers and culture conditions were established by Dr.
MN Gnanapragasam (50). Both wild type and EKLF -/- cells were cultured in 6-well
plates. Expansion media consisted of Stemspan serum-free expansion medium (SFEM),

0.4% of lipids, 500uL of penicillin/streptomycin, 2U/mL hEPO, 100ng/mL mouse stem
cell factor (mSCF), 40ng/mL mouse insulin-like growth factor (mIGF) and 10-6 M
dexamethasone. Terminal differentiation was performed on gelatin coated plates. Cells
were washed and cultured for three days in differentiation media consisting of IMDM,

2U∕mL hEPO, 10ng∕mL mSCF, 12.7 μL∕100mL 1:10 monothioglycerol (mtg), 10%
KnockOut serum replacement, 10% Protein-Free Hybridoma Media II, and 5% plasmaderived serum.

2.2 Western Blot

Collected cells were pelleted and lysed to extract protein in a 1:500- solution of

protease inhibitor cocktail (PIC) and radioimmunoprecipitation assay buffer (RIPA). A
bicinchoninic acid (BCA) protein assay was run on the sample using albumin standards
to establish a standard curve. For the electrophoresis, a 12% polyacrylamide gel was
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loaded with 20-40ug of each sample. The gel was electrophoresed with a 5x SDS loading
buffer, and the protein was transferred onto a polyvinylidene difluoride (PVDF)

membrane. The membrane was rinsed twice with phosphate buffered saline and 0.1%
Tween-20 (PBST) then blocked for 15 minutes with 5% milk. After rinsing, the primary
antibody (see Table 1) was applied at the dilution recommended by manufacturer and

incubated at 4°C for a minimum of two hours. After rinsing, the secondary antibody was
applied at the recommended dilution, incubated for one hour and rinsed a final time.

Imaging of the blot was done with a Li-Cor Odyssey Fc Imaging System.
2.3 Quantitative Polymerase Chain Reaction (qPCR)
Collected cells were pelleted using ultracentrifugation. RNA was then harvested
using a mixture of Trizol and chloroform. A DNase digestion was run to purify the RNA

sample. Resultant RNA was used to make complimentary DNA (cDNA) using qScript
cDNA synthesis kit from Quantabio. In a 96-well plate 1uL of cDNA was added with

200uL of a mixture including primers (see Table 2) and FASTMIX PERFECTA-SYBR

GREEN mix from VWR, each sample was run in triplicate. The qPCR was run on CFX
(BIORAD) Connect Real-Time PCR Detection System.

2.4 Polysome Profiling

Fifty microliters of HUDEP2 cells were grown to a density of 1.75x107 cells/mL.
Cycloheximide from Sigma was introduced to a final concentration of 100ug/ml and
allowed to incubate for 10 minutes before harvesting. Harvested cells were pelleted and

lysed using a lysis buffer containing 10mM 4-(2-hydroxyethyl)-1
piperazineethanesulfonic acid (HEPES) KOH, 2.5mM MgCl2, 100mM KCl, 1mM
dithiothreitol (DTT), 0.1% nonidet P-40 (NP-40), 100U/mL RNase inhibitor, 100ug/mL
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cycloheximide. Cells suspensions were homogenized by passing through a 25-gauge

needle 15 times in a span of 15 minutes. Cellular debris and mitochondria were then
removed by centrifuging at 6,000 rpm for 15 minutes. A260/280 absorbance was

determined on a NanoDrop 2000 Spectrophotometer from Thermo Scientific. Dilutions
of 10 OD units each were then added to tubes with a 10-50% sucrose gradient. After

centrifugation at 18,000 rpm for 18 hours, a Beckman SW32 1 rotor fractionator was
used to separate layers into 14 separate tubes. RNA was harvested from each tube,

followed by qPCR analysis on each fraction.
2.5 Steady State mRNA Analysis (Click iT Nascent RNA capture)
To tag and purify newly synthesized transcripts, Click-iTTM Nascent RNA

Capture Kit (Thermofisher Scientific) was used according to manufacturer’s protocol.

Briefly, HUDEP2 cells were pulsed with EU (a uridine homolog) for 1hr and harvested.
After washing off the EU, chase was performed, and cells were harvested at the 24-hour
time point. RNA was isolated from the 0 and 24 hour harvested cells using Trizol. EU

labeled RNA was tagged with biotin using the Click-iTTM chemistry kit which pulled
down the labelled RNA. The pulldown was done using a streptavidin magnetic bead
followed by cDNA synthesis. Quantification of cDNA was performed using PCR.
2.6 Plasmid Design

Plasmid for INCENP knockdown was designed using a B10 m-orange AID
vector. Primers for INCENP were designed with restriction enzyme sites at ends. After

amplification with polymerase chain reaction (PCR) the sample was electrophoresed
through an agarose gel to separate fragments from full plasmids. The DNA was extracted

from the gel using a mini-prep kit and the ends dephosphorylated using calf intestinal
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alkaline phosphatase (CIAP). The vector was cut using the same restriction enzymes and

ligated with the INCENP fragments using ligase. Directionality was verified via agarose
gel and plasmid was sent out for sequencing.
2.7 Bacterial Transformation

The designed INCENP plasmid DNA was transfected into Escherichia coli (E.

coli) for plasmid amplification. To do this E. coli were heat shocked in a 42°C water
bath followed by an ice bath. Plasmids were then added, and the mixture was transferred
to 1mL of lysogeny broth (LB) and placed in a shaker at 37°C, 225rpm for 1 hour. After

using the mixture to create a lawn on an agar plate containing the appropriate selection
antibiotic, the plate was incubated overnight. Single colonies were each placed into
individual tubes containing 2mL of broth and 2uL of appropriate antibiotic then

incubated in the shaker overnight. Mini-prep was performed to harvest DNA the next
day. These samples were then checked for directionality and sent for sequencing.
Transfection and Transduction: To create viruses for DNA lentiviral transduction,

293T cells were grown in a 6-well plate using Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) until 40-60% confluency. In

a tube a mixture of Opti-mem, PAX, PMD and DNA were carefully mixed. After
incubating 5 minutes, Extreme Gene was added then incubated for 15 minutes. The
contents of one tube were added per well. Three days later the media from each well was

harvested and syringe filtered. This media contained virus used for transduction of
primary cells.

Transduction of cells was done using either retronectin plates or spinoculation.
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2.8 Cell Staining

Erythrocytes were stained for evaluation of F-cell content by using a Modifed
Kleihauer-Betke procedure (Sigma-Aldrich 285C). Slides were air dried for a minimum

of 10 minutes then immersed in Ethanol fixative for 5 minutes before washing and air
drying again. Slides were then immersed in 37°C Citrate Phosphate Buffer solution for 5

minutes, agitating at 1 and 3 minutes. After rinsing and air drying again, slides were
stained for 3 minutes with Acid Hematoxylin Solution then rinsed. 0.1% Eosin B

Solution was used to counterstain for 4 minutes before a final rinse and dry.

For observation of nuclear morphology, harvested cells were cytospun at 500g for
5 minutes and air dried. MGG staining was performed using May-Grunwald solution for
3 minutes, washed with water three times followed by staining with Giemsa for 18

minutes. After washing three more times, slides were allowed to air dry.

All slides were imaged on a bright field microscope at 40x. Images were
processed using FIJI (Fiji Is Just Image J) software.
2.9 Statistics

For determining statistical significance, unpaired 2-tailed t-tests were used.

Statistical significances were represented as follows; P > .05 = NS; P < 0.05 = *; P<0.005
= **; P<0.0005 = ***.

2.10 Ethics
Human blood samples were collected from study volunteers after IRB approval

from Cleveland State University.
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Table 1. Antibodies Table
Antibody

Number

Vender

hy-globin

39386S

Cell Signaling

hβ-globin

84934s

Cell Signaling

hPUM1

12322s

Cell Signaling

hGAPDH

G8795 - 100UL SIGMA

Sigma-Aldrich

hKLF1

7B2

mINCENP

15283

Gift from Dr. James
Bieker, Icahn School of
Medicine in Mount Sinai,
New York
Sigma-Aldrich

Table 2 Primers Table
PCR Primers

Code

hy-globin FP #1

GTGGATCCTGAGAACTTCAA

hy-globin RP #1

GAGCTCAGTGGTATCTGGAG

hy-globin FP #2

GTGAATGTGGAAGATGCTGGAG

hy-globin RP #2

TTCTTGCCATGTGCCTTGAC

hHBG1 FP

ACTTCCTTGGGAGATGCCAC

hHBG1 RP

AAAGCCTATCCTTGAAAGCTCTGA

hHBG2 FP

ACTTCCTTGGGAGATGCCAT

hHBG2 RP

GCCTATCCTTGAAAGCTCTGC

hβ-globin FP

GTTCACTAGCAACCTCAAACAG

hβ-globin RP

GCCCATAACAGCATCAGGAG

hPUM1 FP

CAGATCATTCAGTTTCCCAG

hPUM1 RP

GACAGTACAGAATTGACCTC

hGAPDH FP

GTTTCTATAAATTGAGCCCGCAG

hGAPDH RP

GCAACAATATCCACTTTACCAGAG

mINCENP FP

TATTTCGAAGCCATGGGGACGACGGCCCCA

mINCENP RP

TATGCTAGCTCAGTGCTTCTTCAGGCTGTA
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CHAPTER III

RESULTS

Project 1

3.1 PUM1 Knockdown
The most widely used cell to study hemoglobin switching is human umbilical
derived erythrocyte progenitor (HUDEP2). This line was created using CD34+ cord blood

and immortalized with the introduction of E6/E7 transgenes from human papilloma virus
16 (HPV16). It expresses β-globin just as an adult erythrocyte does despite its origins (52).

Purchased shRNA was utilized to knockdown PUM1 levels in these cells. A modest

knockdown of approximately 30% was achieved. The knockdown was enough to influence
y-globin mRNA levels and qPCR showed that transcript levels of y-globin increased by

2.5-fold. This demonstrates that even small changes in PUM1 levels have an impact on γglobin.
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Figure 8 Decrease in PUM1 levels result in modest increase in y-globin mRNA levels
Plasmids were used to introduce shRNA for knockdown of PUM1 in HUDEP2
cells. Knockdown cells (KD) showed a 2.5-fold increase in y-globin transcript levels by
qPCR as compared to wild type (NTC - No Target Control). β-globin levels are not
significantly affected by the change in PUM1 levels. *P<0.05, **P<0.005
3.2 PUM1 Western Blot

Given the increase in y-globin mRNA transcripts, it is expected that protein levels
would also increase. A western blot was run to verify these changes. Surprisingly the γ-

globin protein levels not only increased but they increased by a much larger degree.

Quantification showed a 12-fold increase in y-protein levels when PUM1 is levels are
decreased while β-globin remains unaffected. The disparity between transcript levels and

protein levels are possible by way of either transcripts not degrading and so being
translated for a longer timespan or an incredible increase in translational efficiency.
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Figure 9 Decrease in PUM1 levels result in a large increase in y-protein levels
Despite a limited knockdown of PUM1 levels in cells, Western blot shows a very
large increase in y-globin protein levels. Quantification reveals an over 12-fold increase
in y-globin, while β-globin levels remain unaffected. * P<0.05, ** P<0.005

3.3 Gamma Globin Transcript Stability
To determine if y-globin transcripts are escaping degradation in the presence of

PUM1, the mRNA half-life needed to be assessed. We tagged nascent mRNA with a
uridine homolog and then washed the cells and took samples at 0 and 24 hours. The

samples taken were steady state and allowed us to ascertain the levels newly made
mRNA at time of tagging, then compare it to how many of those tagged mRNA remained

in the cell 24 hours later. While some mRNA are known to have shorter half-lives,
globin mRNA are known to be extremely stable and generally have a half-life of 24
hours. Samples collected contained only the tagged mRNA which were then analyzed
with qPCR quantification. The results will show if transcript stability, its level after 24
hours, will be affected when PUM1 levels are decreased.

It is here that the difference between HBG1, which contains two putative PUM1
binding sites on its 3’ UTR (Figure 4) and HBG2 which does not, are appreciated. Both
β-globin and HBG2 transcript half-life show no change when PUM1 levels are decreased.

However, HBG1 transcript half-life is significantly increased in knockdown cells. This
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reveals that PUM1 binding to HBG1 mRNA and marking it for degradation as it has been

known to do for its mRNA targets in other cell types. Again, as no other cell type
contains hemoglobin, this is the first time that this interaction has been identified and

investigated.

Figure 10 Tagging of nascent mRNA shows decrease in PUM1 levels result in
increased stability of HBG1 transcripts
Nascent mRNA was labeled then washed so that steady state transcripts would be
tagged. Samples collected at time points 0 and 24 hours show that decrease in PUM1
levels only effect the stability of HBG1. Other transcripts show no significant change
due to only HBG1 containing a PUM1 binding site on 3’ UTR. **P<0.005
3.4 Gamma Globin Polysome Profile

Another factor that can explain the occurrence of the much larger HBG1 protein
level versus transcript level is an increase in translational efficiency. The presence of

transcripts is not an indicator of the rate at which they are being translated into protein.
To investigate translational efficiency, a polysome profile was performed. Cells were

treated with cycloheximide to stop active translation and keep ribosomes from
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dissociating from bound ribosomes. After lysing cell contents are centrifuged in a
sucrose gradient that separates the contents into layers by density. A fractionator was
used to separate the thin layers, or fractions, into individual tubes for analysis by qPCR.

Optical density (OD) was also gathered via spectrophotometer for each layer so that the
density of the cellular contents could be determined. The OD allowed for identification

of which fractions contained monosomes and which fraction contained polysomes.
Polysomes are an indicator of active translation, while monosomes are

contraindicative. Our results show that when PUM1 levels are decreased there is a
significantly larger amount of polysomes on HBG1, indicating greater translational

efficiency. As expected, translation efficiency was not affected for the other globin
proteins.
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Figure 11 Polysome profiling shows decreased levels of PUM1 result in increased
translational efficiency for HBG1
Actively translating mRNA are bound to polysomes, mRNA that is not actively
translating have no ribosomes or a monosome. Here, polysome profiling shows a
significant increase in polysome levels occurring on HBG1 when PUM1 levels are
lowered. Translation levels of other globin levels are unaffected. *P<0.05, **P<0.005
Collaboration with Arnab Gish in Dr. Komar lab at Cleveland State University
3.5 PADDAS Patient F-cell Staining

Erythrocytes that contain a significant proportion of HbF are called F-cells.
These cells exhibit a dark edge compared to normal erythrocytes under microscopic
examination. IRB approval was granted by Cleveland State University and blood smear

slides for a patient with PADDAS. The patient has a novel frameshift mutation of the
PUM1 binding site which causes a proline to replace a histidine, followed by 16 new
amino acids and a premature stop codon. A healthy parent sample was also obtained for

evaluation. All cells were stained for F-cells using a modified staining method which
takes advantage of the fact the F-cells are more resistant to acid. F-cells exhibit a distinct
border while other erythrocytes do not. Cells for both patient and parent were counted,
and statistical analysis run.
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Over 15,000 cells on 4-8 fields were counted for both samples. The parent slide
showed a normal number of F-cells with <1% observed. However, the patient sample
contained a significantly larger number with over 6% F-cells. This indicates that when

PUM1 is unable to bind properly that y-globin is expressed at higher-than-normal levels

in vivo.

Figure 12 Selective staining for F-cells in circulating blood shows a significantly
higher percentage of F-cells in patient sample versus healthy parent
Blood samples from a patient with a novel heterozygous frameshift mutation
resulting in PADDAS as well as a healthy parent were investigated. The mutation alters
the PUM1 binding site, making it difficult for PUM1 to bind to targets. Cells were
stained for F-cells and then over 15,000 cells for each were counted. The healthy parent
shows normal F-cell levels for an adult of <1%. The patient showed a significantly
higher amount. This in vivo example shows that lowered ability of PUM1 to bind allows
for an increase in y-globin production. P<0.005

Project 2
3.6 INCENP Knockdown

When investigating the role of INCENP we used murine Extensively Self
Renewing Erythroid (mESRE) cells which differentiate to the point of enucleation.

These are an ex vivo primary cell culture.
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Using purchased shRNA, the INCENP levels were knocked down in WT cells.

Knockdown was verified by both western blot and qPCR analysis.

Figure 13 Western blot and qPCR show successful INCENP knockdown
Purchased shRNA was used to knockdown INCENP levels. Western blot shows
decrease in protein levels and qPCR quantification shows an approximately 0.8-fold
reduction in INCENP transcripts. ***P<0.0005
3.7 Nuclear morphology analysis

A single experiment was run and mESRE cells were allowed to differentiate

according to protocol. Cytospin slides were made from the samples and stained with
May-Grundwald Giemsa stain. The cells were observed for nuclear morphology and
counted as normal or abnormal. Any nuclear morphology other than a single nucleus,
such as multi-nucleate or nuclear bridging between cells, was counted as abnormal.

Three slides for each condition were read containing approximately 150-200
undifferentiated cells and 400-450 differentiated cells. The difference in cell counts

being due to a difference in cellular density on slides. Percentage of multinucleate

morphology per condition were compared for analysis. Results show that a decrease in
the level of INCENP lead to an upward trend in multinucleate nuclear morphology.
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While distinct binucleate cells were observed, there were also globular nuclei that may

have been multi-nucleate as well as instances of distinct nuclear bridging between cells.

Figure 14 Decrease in INCENP levels result in an upward trend of multinucleate
cell morphology
In a single experiment, mESRE cells were differentiated and affixed to slides
using cytospin then stained with MGG. Analysis of cells the percentage of multinucleate
cells per condition showed an upward trend in multinucleate cell morphology when
INCENP levels are reduced.
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CHAPTER IV

DISCUSSION

The purpose of this research is to investigate the roles of two novel targets of the

master erythroid transcription factor EKLF, and their roles in erythropoiesis. Previous
research has shown that EKLF plays a large role in many aspects of erythropoiesis
including exiting the cell cycle for enucleation and hemoglobin switching. The first
target investigated, PUM1, has been previously studied for its role in many aspects of
body development and size regulation, as well as its role in cancer development. It has

been shown to often act as a post-transcriptional repressor with cell type specific roles.
Repression is generally achieved by binding to target mRNA, shortening transcript

stability and blocking effective translation.

Our research showed that decreased PUM1 levels in erythroblasts resulted in an
increase in overall y-globin expression while not affecting β-globin expression.
Sequencing of all the globin genes showed that HBG1 is the only gene with two putative
PUM1 binding sites on its 3’ UTR. Native RNA-immunoprecipitation (RNA-IP) showed
that PUM1 only directly interacts with fetal y-globin mRNA (data not shown).
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Further, our data showed that decreased PUM1 levels increased y-globin protein
levels by 12%, while transcript levels were only increased by 2.5%. Possible

explanations for this occurrence are y-globin transcripts being translated at an unusually
high rate, or the transcripts failing to degrade. Knowing that PUM1 has been shown to

both shorten mRNA half-life and block translation, we explored those possible

explanations.
To determine if PUM1 plays a role in transcript half-life, an analysis was

performed on the degradation rate of mRNA. Globin genes have shown to be extremely
stable and have a half-life of approximately 24 hours. In our experiment, nascent mRNA

was tagged and washed, after which samples were taken at time points 0 and 24 hours.
Transcript levels for these samples were evaluated with qPCR. Results showed that β-

globin and HBG2 half-lives are unaffected in both wild type (shNTC) and PUM1

knockdown (shPUM1), while HBG1 saw a significant increase in half-life in shPUM1
samples. This shows that PUM1 directly affects only the half-life of HBG1 and has no
observable effect on other globin levels. Therefore, the upregulation of PUM1 in

terminal differentiation results in PUM1 marking HBG1 transcripts for degradation at
high rates, driving HBG1 levels down in adult erythrocytes.

Polysome profiling was used to examine translation efficiency in both WT and

PUM1 knockdown cells. Polysomes show active translation, while monosomes indicate

a lack of translation (53). Our results showed a significant increase in polysome activity
for HBG1 in knockdown cells. This increase in translation activity was seen only on
HBG1 but no other globins, indicating once again that PUM1 has a unique and direct

effect on HBG1, in this case on its translational efficiency.
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An in vivo example of PUMl’s significance was observed in the blood of a
patient with Pumilio 1-associated developmental disability, ataxia, and seizure

(PADDAS) harboring a novel PUM1 frameshift mutation resulting in an amino acid
substitution, 16 new amino acids, and a premature stop codon. Samples of both the
patient and the parent were stained to look for F-cells. Cell counts were performed and

showed that while the parent exhibited normal levels of F-cells, the patient had a
significantly higher level. This demonstrates that in a patient where PUM1 is unable to

properly bind to HBG1, y-globin will be expressed in higher levels.

Together, this data shows that in adults PUM1 binds to the 3’ UTR of only HBG1
mRNA and represses fetal y-globin protein expression. It accomplishes this by means of

both shortening transcript half-life and inhibiting effective translation. While it has been

proven in previous studies that EKLF has a role in fetal hemoglobin silencing by

activating transcriptional repressor proteins, this research elucidates an addition

mechanism in the process. Given that even small changes in PUM1 levels can greatly
affect y-globin expression while not effecting other globins, this is a possible avenue for
further research for developing treatments for β-hemoglobinopathies.

Preliminary investigation into the role of the novel EKLF target INCENP was
also performed. Both wild type and EKLF -/- primary cells were used in this project.

For knockdown of INCENP levels in WT cells, purchased shRNA plasmids were used.
Analysis of the nuclear morphology showed a trend of increase in multi-nucleation post

differentiation in knockdown (shINCENP) cells versus wild type (shNTC). DNA
bridging was also observed and counted as multi-nucleate cells. This bridging may be a
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direct result of a dysfunctional chromosomal passenger complex (CPC) failing to block
abscission due to unsuccessful chromosomal migration in anaphase.

Next, we sought to observe if using plasmids to express INCENP in EKLF -/

cells would rescue INCENP levels and ploidy. Introducing the AID containing plasmid
via transduction proved difficult. After several attempts, western blot results indicated

that overexpression was marginally successful. However, while target protein levels

looked promising, the loading control signal consistently showed an uneven protein load.
It is possible that this was caused by fastidious cells in the process of dying, which can
alter protein levels in unusual ways even when using BCA to assure consistent protein
levels.

Unfortunately, attempts to explore the effectiveness of the AID by exposing cells
to various auxin concentrations had the same difficulties on western blot. While the
levels of the targeted proteins were promising, the loading controls were still not

consistent. Despite several attempts, the efficacy of the AID was unable to be properly
evaluated.

Multiple attempts were made to differentiate the overexpression cells, but none
were successful. Despite being plated on fresh gelatin plates, the cells did not adhere as
seen in previous differentiations. Two different preparations of gelatin were utilized but

the cells still failed to adhere. It is unknown if the source of the failure is the gelatin, the

media preparation, or something else. The source of the problem remained unknown
during the study, despite repeated and thorough troubleshooting.

It is possible that a different plasmid vector would be helpful, since the vector
used in this study contained a mOrange tag. Plasmids with AIDs tend to be large and
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Although we used a transduction strategy

primary cells are often difficult to transfect.

to deliver the sequences of interest into the cells, a vector that is smaller, while still

containing the AID may prove more useful, and is certainly worth exploring in future

experiments.
Essentially, for INCENP the knockdown results on nuclear morphology were

initially promising, but there was not any data gathered after that initial exploration due
to technical difficulties. However, it did provide information on what steps should be

avoided or changed when this research is continued. This is an opportunity for further

research with a redesigned AID plasmid and continued attempts at successful

differentiation.
Altogether this data shows that EKLF, the master transcription factor for

erythropoiesis, upregulates the synthesis of both PUM1 and INCENP during terminal
erythroid differentiation. These are novel targets, and both have not been studied in
erythroid cells until now. PUM1 aids in hemoglobin switching by repressing y-globin

expression after birth through direct targeting of the HBG1 transcripts. The stability and
translational efficiency of the transcripts are compromised, leading to repression.
As a member of the chromosomal passenger complex, INCENP plays a role in

maintaining successful cytokinesis during the quick passage through the terminal

differentiation stages. It may be that the increased levels during erythropoiesis are
essential for maintaining chromosomal and nuclear integrity during that time. This initial

exploration showed an upward trend in unsuccessful cytokinesis when INCENP levels
are lowered, making it a possible avenue for future research. Figure 15
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Figure 15 During terminal erythroid differentiation EKLF upregulates the
expression of PUM1 which represses y-globin and INCENP which aids in successful
cytokinesis
While much previous research has shown EKLF to be the master transcription
factor in erythropoiesis, its many roles are still being explored. This research shows that
the novel EKLF targets PUM1 and INCENP have important roles in erythropoiesis.
PUM1 functions as a post transcriptional repressor of y-globin, making it a novel
mechanism in hemoglobin switching. INCENP, a member of the chromosomal
passenger complex, has an important role in successful cytokinesis.

This promising research has increased our current understanding of the erythroid

master transcription factor EKLF. Also, it has identified a previously unknown major

mechanism in hemoglobin switching. This data will be instrumental in developing future
therapies and treatments of β-hemoglobinopathies. Further, this research has also

identified a possible future research direction in clarifying the role of INCENP in

erythropoiesis.
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